Back to top
more

Horizon Pharma Public Limited Company (HZNP)

(Delayed Data from NSDQ)

$26.54 USD

26.54
1,058,972

+0.55 (2.12%)

Updated May 3, 2019 04:00 PM ET

After-Market: $26.52 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Horizon's (HZNP) Tepezza Meets Goals in TED Expanded Use Study

Horizon Therapeutics (HZNP) announces positive top-line data from its phase IV study of Tepezza to expand its indication to include TED in adult patients with chronic/low clinical activity scores.

Community Health (CYH) Divests Hospital for $92 Million

Community Health (CYH) divests a healthcare facility in West Virginia, thereby reinforcing the sincere focus that it puts to shed non-core assets and use funds to grow well-performing business areas.

Horizon Therapeutics (HZNP) Down 0.9% Since Last Earnings Report: Can It Rebound?

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

Here's What is Driving Amgen (AMGN) Stock's Outperformance

Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. It is also rapidly advancing its robust pipeline.

3 Reasons Growth Investors Will Love Horizon Therapeutics (HZNP)

Horizon Therapeutics (HZNP) possesses solid growth attributes, which could help it handily outperform the market.

Here's Why Horizon Therapeutics (HZNP) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

Alkermes (ALKS) Stock Up 15% in Six Months: Here's Why

Alkermes shares have surged in the past six months, owing to strong sales performance of its new drug Lybalvi and its decision to separate the oncology unit.

Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar?

Style Box ETF report for QQQJ

Horizon's (HZNP) Q4 Earnings and Revenues Surpass Estimates

Horizon Therapeutics (HZNP) reports better-than-expected fourth-quarter 2022 results as it beats the Zacks Consensus Estimate for both revenues and earnings.

Horizon Therapeutics (HZNP) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Horizon Therapeutics (HZNP) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Horizon Therapeutics (HZNP) Q4 Earnings and Revenues Top Estimates

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 11.01% and 1.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Sanghamitra Saha headshot

How Are Biotech ETFs Reacting to Q4 Earnings Releases?

The latest earnings from some of the big biotech players came in at mixed this reporting season.

Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?

Smart Beta ETF report for EUSA

Is Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) a Strong ETF Right Now?

Smart Beta ETF report for GSEW

Incyte (INCY) Tops Q4 Earnings and Revenue Estimates

Incyte (INCY) delivered earnings and revenue surprises of 5.08% and 4.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Amgen (AMGN) Beats on Q4 Earnings, 2023 Sales View Disappoints

Amgen (AMGN) beats Q4 estimates for earnings and sales. It launches Amjevita in the United States, which is the first biosimilar of Humira to be launched in the country.

Amgen (AMGN) to Report Q4 Earnings: What's in the Cards?

Volume growth from Amgen's (AMGN) key drugs like Prolia, Otezla, Repatha and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

Horizon (HZNP) Dazodalibep Meets Goal in Sjogren's Syndrome Study

Horizon Therapeutics (HZNP) announces that a phase II Sjogren's syndrome study of its candidate, dazodalibep, meets the primary endpoint for the second population.

HZNP vs. RGEN: Which Stock Is the Better Value Option?

HZNP vs. RGEN: Which Stock Is the Better Value Option?